Article and Video CATEGORIES

Cancer Journey

Search By

Patterns of Acquired Resistance to EGFR TKIs in EGFR Mutation-Positive NSCLC
Thu, 10/22/2015 - 06:00
Author
GRACE Videos and Articles
GRACE Cancer Video Library - Lung

GCVL_LU_Acquired_Resistance_Patterns_EGFR_TKIs_Mutation-Positive_NSCLC

 

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.

 

Transcript

For patients with EGFR mutant lung cancer, we generally recommend initial therapy with an EGFR tyrosine-kinase inhibitor — so, that’s gefitinib, erlotinib, or afatinib. We generally see significant tumor shrinkage with these drugs, but after time, patients eventually develop resistance to these therapies. The time until resistance really can vary dramatically, from three months, to even a few years down the road, but eventually patients do develop resistance. 

How that resistance manifests is really important for deciding how to deal with the consequences of resistance. So, if we see resistance develop in a  handful of sites and it’s very slow growth, we may actually just monitor that disease progression, acknowledging that the disease is beginning to become resistant, but recognizing that we don’t want to make changes in therapy too quickly. Importantly, if there is a single site of resistance, and if it’s a site that may cause symptoms or a site that is causing symptoms, such as a painful boney metastasis, it’s a very reasonable approach to target just that site that’s developing resistance, so that we can continue controlling the rest of the body with the oral medication, and then control the single-site progression — for instance, if a lung nodule has popped up that wasn’t there before, and is growing, it would be reasonable to consider radiation therapy for that lung nodule, or even, in some cases, surgical resection of that lung nodule to remove that resistant nodule, and observe how patients do afterward.

In a retrospective series from my institution, we took a handful of patients who had been treated this way — where, after a single site of resistance developed, we did radiation or surgery, for that site of resistance, and we found that the time until we had to make a change in their systemic therapy, i.e., drop the EGFR tyrosine-kinase inhibitor, or add chemotherapy, was over a year for most patients. And so, as a consequence, I think we spared a change in therapy for a year, and we generally helped patients. 

Now, of course, this needs to be studied more, but I think this is a reasonable strategy for patents with single-site resistance.

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi Sean,


Welcome to Grace. I'm so sorry you're going through this. I can only imagine your worry about metastases and I hope that's not the case.
Liver hemangiomas are thought...

n3p, Hi and welcome to Grace. I'm sorry you have to check for new nodules. It does sound like your onc has good reason not to be alarmed that you have...

Thanks for the thoughtful response, I really appreciate that! All your points make sense. I will check back in later.

Please do check back in. It looks like I forgot to paste in links for that article. I'm going back to edit in the links.

Hi blp2020, 


Welcome to Grace. I'm sorry you're having trouble. It would be very extremely rare to find a pancoast tumor in person your age. They are normally found in older...

Hi Sel87, Welcome to Grace.  I'm so terribly sorry that your mother is going through this.  I'm going to assume that there are no brain mets found, so let me know...

Recent Comments

JOIN THE CONVERSATION
Hi Sean,
Welcome to Grace. …
By JanineT Forum … on Thu, 02/02/2023 - 14:57
Thank you Janine I…
By Cari on Tue, 01/31/2023 - 19:23
There are a lot of good…
By Cari on Tue, 01/31/2023 - 14:47
Scans
By Cari on Tue, 01/31/2023 - 12:41